CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies — marred by the death of a patient – Endpoints News
Over the past 7 years, Calico has been so much more than your average, run-of-the-mill secretive biotech players. It’s a riddle, wrapped in a mystery, inside an enigma, to repurpose an old Winston Churchill line dating from the time he confronted the Iron Curtain surrounding Stalin’s thoughts.
Launched by industry legend Art Levinson of Genentech fame, with the infinitely deep pockets of Google for support, one of the few big headlines the anti-aging biotech has sparked focused on a major alliance with AbbVie — a giant outfit that conversely likes to show off its drug prospects whenever it can. Together, they’ve been focused on diseases that limit life span — quite an arc of ailments.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it’s free.
Published at Wed, 21 Oct 2020 11:00:00 +0000